Abstract
Objectives This pilot study examines effectiveness of an innovative pharmacy design change on over-the-counter (OTC) medication misuse in older adults (ages ≥65). Few interventions have attempted to decrease older adult OTC misuse, and none have addressed system barriers. A structural redesign of the pharmacy (the Senior Section™) was conceptualized to increase awareness of higher-risk OTC medications. The Senior Section contains a curated selection of OTC medications (for pain, cough/cold, allergy, sleep) and is close to the prescription department to facilitate pharmacy staff/patient engagement to reduce misuse.
Methods A pre-/post-implementation design was used to recruit 87 older adults from three pharmacies. Using a hypothetical scenario, participants selected an OTC medication, which was compared to their medication list and health conditions, and their reported use was compared against the product labeling. Four misuse outcomes were determined: (1) Drug/Drug, (2) Drug/Disease, (3) Drug/Age, and (4) Drug/Label with five sub-types. Patient characteristics were collected and compiled into a propensity-score matching logistic regression model to estimate their effects on the Senior Section’s association with misuse outcomes at pre-/post-implementation.
Results Patient characteristic were uniform between pre-/post-implementation and, once entered into a propensity-score matching model, Drug/Disease Misuse significantly lessened over time (z=-2.09, p=0.037). The Senior Section reduced Drug/Drug Misuse, but not significantly. Drug/Label Misuse varied according to the sub-type, with reduced Daily-Dosage (z=-2.42, p=0.016) and Single-Dosage misuse (z=-5.82, p=0.001); however, Timing/Frequency misuse increased (z=2.16, p=0.031).
Conclusions These nascent outcomes support a well-conceived pharmacy-based OTC aisles redesign as valuable for reducing older adult OTC medication misuse. The Senior Section, when broadly implemented, would create new permanent structures and processes to assist older adults in accessing risk information for confidently selecting safer OTC medications.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.ncbi.nlm.nih.gov/pubmed/28130022
Funding Statement
This work was supported by the Agency for Healthcare Research and Quality [grant number R18HS024490]; and the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [grant UL1TR000427 (now UL1TR002373)].
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
aaron.gilson{at}wisc.edu
jamie.stone{at}wisc.edu
amorris4{at}wisc.edu
roger.brown{at}wisc.edu
kzxiong2{at}wisc.edu
najacobson{at}wisc.edu
rjholden{at}iu.edu
Cynthia.Phelan{at}aurora.org
smalbert{at}pitt.edu
denise.pigarelli{at}wisc.edu
robert.breslow{at}wisc.edu
lauren.welch{at}va.gov
michelle.chui{at}wisc.edu
Authors’ Contributions statement: Conceptualization – MAC, JAS
Data curation – JAS, AOM, KZX, AMG
Formal analysis - RLB, AMG
Funding acquisition - MAC
Investigation – KZX, JAS, MAC, DLWP, RMB, LW, AOM
Methodology – MAC, AMG, AOM
Project administration - JAS
Resources – n/a
Software - RLB
Supervision - MAC
Validation – JAS, KZX, AOM
Visualization – AMG
Writing – original draft – MAC, AOM, JAS, AMG
Writing – review & editing – NJ, CHP, RLB, RJH, SMA, DLWP, RMB, LW, MAC, AOM, JAS, AMG, KZX
Data Availability statement: No data are available.
Competing Interests statement: The authors report no competing interests.
Funding statement: This work was supported by the Agency for Healthcare Research and Quality [grant number R18HS024490]; and the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [grant UL1TR000427 (now UL1TR002373)]. The content is solely the responsibility of the authors and does not necessarily represent the official views of either the Agency for Healthcare Research and Quality or the NIH.
Data Availability
No data are available.